Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000905718-21-000513
Filing Date
2021-04-01
Accepted
2021-04-01 16:31:17
Documents
2
Period of Report
2021-03-22

Document Format Files

Seq Description Document Type Size
1 sonnet_fm3mar222021.html 3  
1 sonnet_fm3mar222021.xml 3 1641
2 POWER OF ATTORNEY poa.htm EX-24 5283
  Complete submission text file 0000905718-21-000513.txt   8518
Mailing Address 100 OVERLOOK CENTER SUITE 102 PRINCETON NJ 08540
Business Address 100 OVERLOOK CENTER SUITE 102 PRINCETON NJ 08540 609-375-2227
Sonnet BioTherapeutics Holdings, Inc. (Issuer) CIK: 0001106838 (see all company filings)

EIN.: 522102141 | State of Incorp.: DE | Fiscal Year End: 0930
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O IMMUNE DESIGN CORP. 1616 EASTLAKE AVE. E, SUITE 310 SEATTLE WA 98102
Business Address
Kenney Richard T (Reporting) CIK: 0001606653 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-35570 | Film No.: 21798484